Better EFS Outcomes with Perioperative Durvalumab Plus FLOT Than with Placebo Plus FLOT for Resectable Gastric or GEJ Adenocarcinoma By Ogkologos - June 10, 2025 643 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MATTERHORN study Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR 38% of Recurrent Breast Cancers Have a Different HER2 Status than... May 25, 2021 Opioid Use Drops Among Cancer Patients at End of Life August 20, 2021 The Nobel Prize winner helping us treat children’s cancers November 8, 2022 Oncology Dietitians Don’t Usually Inquire About Food Insecurity in Cancer Patients,... February 12, 2022 Load more HOT NEWS Ibrutinib-Containing Immunochemotherapy in Front-Line Treatment of Young, Medically Fit Patients with... ESMO AI & Digital Oncology Congress 2025 Closed in Berlin under... FDA Approves Pembrolizumab for Adjuvant Treatment of Stage IIB or IIC... Children with Acute Lymphoblastic Leukemia Can Skip Radiation to the Brain
